摘要
目的:探讨脉血康胶囊联合依达拉奉治疗出血性脑梗死患者的疗效及对血清基质金属蛋白酶-9(MMP-9)、S-100β蛋白水平和神经功能的影响。方法:从出血性脑梗死患者中选取76例,随机分成两组。对照组给予依达拉奉,治疗组在对照组基础上配合脉血康胶囊。对比两组患者临床疗效、血清MMP-9、S-100β水平变化、神经功能恢复情况、日常生活能力及不良反应发生率。结果:治疗组总有效率92.11%高于对照组71.05%(P<0.05);两组患者美国国立卫生研究院卒中量表(NIHSS)评分均下降,日常生活能力量表(ADL)评分均升高,且治疗组两项评分改善程度优于对照组(均P<0.05);治疗后第7d、14d两组患者MMP-9、S-100β水平低于治疗前(P<0.05),且治疗组各个时间点均低于对照组(P<0.05);治疗后第3d两组患者S-100β水平均高于治疗前(P<0.05);两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论:脉血康胶囊与依达拉奉联合治疗出血性脑梗死患者疗效显著,可明显改善患者神经功能缺损及日常生活能力,降低血清MMP-9、S-100β蛋白水平,且安全性较高。
Objective： To investigate the effect of Maixuekang capsule combined edaravone on hemorrhagic cerebral infarction patients and its influences on serum matrix metalloproteinase-9 （MMP-9）, S-100β protein levels and nerve function.Methods： 76 cases of hemorrhagic cerebral infarction patients were selected as the research subjects, they were randomly divided into two groups.The control group was given Edaravone, and the treatment group was treated with Maixuekang capsule on the basis of the control group.The clinical efficacy, serum MMP-9 and S-100β protein levels, nerve function recovery, activity of daily living and incidence rate of adverse reactions were compared between the two groups.Results：The total effective rate of the treatment group was 92.11%, which was higher than 71.05% of the control group （ P 〈0.05）; the National Institutes of Health Stroke Scale （NIHSS） score in the two groups decreased, and the Activity of Daily Living Scale （ADL） score increased, the improvement of the two scores in the treatment group was better than that in the control group （ P 〈0.05）;the levels of MMP-9 and S-100 data in the two groups were lower than those before treatment on the 7th and 14th day after treatment （ P 〈0.05）, and the treatment group was lower than the control group at all time points （ P 〈0.05）; at third day after treatment, the levels of S-100β in the two groups were all higher than those before treatment （ P 〈0.05）; there was no significant difference in the incidence of adverse reactions between the two groups （ P 〉0.05）.Conclusion： The combination of Maixuekang capsule and edaravone is effective in treating hemorrhagic cerebral infarction, it can significantly improve nerve function defect and daily living ability, reduce serum MMP-9 and S-100β protein levels, and has higher safety.
作者
张建强
焦永平
Zhang Jianqiang;Jiao Yongping(Department of Neurology,the First Affiliated Hospital of Henan University of Science and Technology（Luoyang 471003)
出处
《陕西中医》
2018年第11期1521-1523,共3页
Shaanxi Journal of Traditional Chinese Medicine
基金
河南省自然科学基金资助项目(162300410103)
关键词
脑梗塞/中医药疗法
@依达拉奉
@脉血康胶囊
Brain infarction/traditional Chinese medicine therapy
@Edaravoneon
@Maixuekang capsule
